Secarna Pharmaceuticals
Secarna appoints Jens Holstein and Richard Mark Engelhard to new Advisory Board
March 25, 2026Secarna Pharmaceuticals
Secarna Pharmaceuticals has appointed Jens Holstein and Richard Mark Engelhard to its new Advisory Board. As part of the board, …
Secarna Pharmaceuticals and Curie.Bio expand existing partnership
March 6, 2026Research and Development Curie.Bio, Secarna Pharmaceuticals, partnership
Secarna Pharmaceuticals has announced the expansion of the existing scientific and strategic collaboration agreement with Curie.Bio. The collaboration, first announced …
Secarna and Vect-Horus collaborate to advance therapies for central nervous system disorders
July 14, 2025Mergers and Acquisitions, Research and Development Neurology, Secarna Pharmaceuticals, Vect-Horus, central nervous system, neurodegenerative conditions
Secarna Pharmaceuticals and Vect-Horus have announced that the companies will collaborate to develop RNA-targeted therapeutics capable of crossing the blood-brain …
Secarna Pharmaceuticals and Curie.Bio portfolio company enter research and option agreement
May 14, 2025Research and Development Corporate, Cure.Bio Portfolio Company, Pharmacy, Secarna Pharmaceuticals, agreement
Global biopharma company, Secarna Pharmaceuticals, and biotech investor, Cure.Bio, have announced signing a research and option agreement, intending to accelerate …
Secarna Pharmaceuticals to announce positive new data at cancer research conference
April 1, 2025Research and Development Oncology, Secarna Pharmaceuticals, oncology, research and development
Secarna Pharmaceuticals will present new preclinical data with its lead programme SECN-15 at the American Association for Cancer Research (AACR) …
